EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A pilot study of chemoimmunotherapy in the postconsolidation setting for high‐risk neuroblastoma (ANBL19P1): A report from the Children’s Oncology Group

Ami V Desai iD, Arlene Naranjo, Brian LaBarre, Lulu Chen, Kelly C Goldsmith, Meaghan P Granger, Lisa States, Sean G Green, Mariel Trunzo, Wendy Fitzgerald, Steven G DuBois iD, Rochelle Bagatell und 2 weitere

Cancer · 2026

DOI: 10.1002/cncr.70165 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer, 2026. Verfasst von Ami V Desai und 13 weiteren Autor:innen. Beteiligte Einrichtung: Section of Hematology, Oncology, and Stem Cell Transplantation, Department of Pediatrics, University of Chicago, Chicago, Illinois, USA. Hauptthemen laut MEDLINE: Neuroblastoma, Antineoplastic Combined Chemotherapy Protocols, Immunotherapy. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: St. Baldrick's Foundation, National Clinical Trials Network Operations Center Grant, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Survival for patients with high‐risk neuroblastoma remains poor despite current‐era multimodality treatment that includes postconsolidation GD2‐directed immunotherapy. Given the promising responses in patients who receive dinutuximab‐based chemoimmunotherapy in the relapsed setting, the Children’s Oncology Group ANBL19P1 study evaluated the feasibility of administering irinotecan, temozolomide, dinutuximab, and sargramostim after frontline consolidation with tandem autologous stem cell transplantation (ASCT).

Methods

Patients with high‐risk neuroblastoma who received induction therapy followed by tandem ASCT and had no evidence of progressive disease (PD) were eligible. Treatment included five 28‐day cycles of temozolomide and irinotecan (days 1–5), dinutuximab (days 2–5), and sargramostim (days 6–12). Isotretinoin (days 8–21) was given during cycles 1–6. Therapy was deemed feasible if the 95% confidence interval placed on the percentage of patients that completed five cycles of chemoimmunotherapy without PD within 30 weeks contained 75% in the absence of excessive toxicity. Event‐free survival and overall survival were determined from the time of enrollment.

Results

Forty eligible patients enrolled, and 35 (87.5%; 95% confidence interval, 73.9%–94.5%) completed five cycles without PD within 30 weeks, meeting the feasibility threshold. No unacceptable toxicities occurred on protocol therapy, including no toxic deaths. Five patients discontinued therapy early because of physician determination ( n = 2), patient/parent refusal of further therapy ( n = 2), and PD ( n = 1). The 2‐year event‐free and overall survival rates were 82.5% ± 6.1% and 92.5% ± 4.2%, respectively.

Conclusions

The administration of chemoimmunotherapy in the postconsolidation setting after tandem ASCT is feasible and tolerable. Future studies will be needed to define the population most likely to benefit from this augmented postconsolidation therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeuroblastomaAntineoplastic Combined Chemotherapy ProtocolsImmunotherapyHumansPilot ProjectsFemaleAntibodies, MonoclonalChild, PreschoolMaleIrinotecanTemozolomideInfantChildIsotretinoinRecombinant ProteinsGranulocyte Colony-Stimulating FactorFeasibility StudiesHematopoietic Stem Cell TransplantationConsolidation ChemotherapyTransplantation, AutologousStem Cell TransplantationGranulocyte-Macrophage Colony-Stimulating Factor

Stichwörter der Autor:innen

anti‐GD2 antibodychemoimmunotherapyhigh‐risk neuroblastomapostconsolidation

Substanzen

Antibodies, MonoclonaldinutuximabIrinotecanTemozolomidesargramostimIsotretinoinRecombinant ProteinsGranulocyte Colony-Stimulating FactorGranulocyte-Macrophage Colony-Stimulating Factor

Autor:innen und Institutionen

  • Section of Hematology, Oncology, and Stem Cell Transplantation, Department of Pediatrics, University of Chicago, Chicago, Illinois, USA.
  • Children's Oncology Group Statistics and Data Center, University of Florida, Gainesville, Florida, USA.
  • Aflac Cancer and Blood Disorders Center at Children's Healthcare of Atlanta and Emory University School of Medicine, Atlanta, Georgia, USA.
  • St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
  • Children's Hospital of Philadelphia, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Lucile Packard Children's Hospital Stanford, Stanford, California, USA.

ORCID-Profile: Ami V Desai, Steven G DuBois

Förderung

  • St. Baldrick's Foundation
  • National Clinical Trials Network Operations Center Grant
  • NCI NIH HHS
  • National Clinical Trials Network Statistics and Data Center Grant

Zitieren

APA

Desai, A. V., Naranjo, A., LaBarre, B., Chen, L., Goldsmith, K. C., Granger, M. P., States, L., Green, S. G., Trunzo, M., Fitzgerald, W., DuBois, S. G., Bagatell, R., Park, J. R., & Marachelian, A. (2026). A pilot study of chemoimmunotherapy in the postconsolidation setting for high‐risk neuroblastoma (ANBL19P1): A report from the Children’s Oncology Group. Cancer. https://doi.org/10.1002/cncr.70165

Vancouver

Desai AV, Naranjo A, LaBarre B, Chen L, Goldsmith KC, Granger MP, et al. A pilot study of chemoimmunotherapy in the postconsolidation setting for high‐risk neuroblastoma (ANBL19P1): A report from the Children’s Oncology Group. Cancer. 2026. doi:10.1002/cncr.70165

BibTeX
@article{Desai2026,
  author = {Desai, Ami V and Naranjo, Arlene and LaBarre, Brian and Chen, Lulu and Goldsmith, Kelly C and Granger, Meaghan P and States, Lisa and Green, Sean G and Trunzo, Mariel and Fitzgerald, Wendy and DuBois, Steven G and Bagatell, Rochelle and Park, Julie R and Marachelian, Araz},
  title = {A pilot study of chemoimmunotherapy in the postconsolidation setting for high‐risk neuroblastoma (ANBL19P1): A report from the Children’s Oncology Group},
  journal = {Cancer},
  year = {2026},
  doi = {10.1002/cncr.70165}
}
Kostenlos starten →